Genedrive PLC Result of General Meeting (1355Z)

TIDMGDR

RNS Number : 1355Z

Genedrive PLC

11 May 2023

genedrive plc

("genedrive", the "Group" or the "Company")

Result of General Meeting

London, UK - 11 May 2023: genedrive plc (LSE: GDR), the point of care molecular diagnostics company, announces that at the General Meeting held earlier today, all resolutions proposed were duly passed by shareholders.

For information, details of the proxy voting are shown below:

 
 Resolutions   Votes For      Vote For     Votes Against   Votes Against   Votes Withheld 
                              (as % of                        (as % of 
                             votes cast)                    votes cast) 
 1.            15,304,609          88.4%       2,001,759           11.6%            1,000 
              -----------  -------------  --------------  --------------  --------------- 
 2.            15,300,609          88.4%       2,005,759           11.6%            1,000 
              -----------  -------------  --------------  --------------  --------------- 
 3.            15,304,609          88.4%       2,001,759           11.6%            1,000 
              -----------  -------------  --------------  --------------  --------------- 
 4.            15,300,609          88.4%       2,005,759           11.6%            1,000 
              -----------  -------------  --------------  --------------  --------------- 
 

The full text of the resolutions can be found in the Notice of General Meeting set out in the shareholder circular published by the Company on 24 April 2023 which is available on the Company's website www.genedriveplc.com.

For further information, please contact:

 
 genedrive plc                                        [phone] 
 David Budd (Chief Executive 
  Officer) 
 Russ Shaw (Chief Financial 
  Officer) 
 
 Peel Hunt LLP - Nominated Adviser, 
  Joint Broker                                        [phone] 
 James Steel / Oliver Duckworth 
 
 finnCap Ltd - Joint Broker                           [phone] 
 Geoff Nash / George Dollemore 
 
 Walbrook PR - Financial PR & IR 
  Adviser                                             [phone] 
 Paul McManus / Anna Dunphy                    Or [e-mail] 
 
 

About genedrive plc ( http://www.genedriveplc.com )

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The company are currently developing a genetic test for CYP2C19 metaboliser status.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMGPUQAAUPWGUG

(END) Dow Jones Newswires

May 11, 2023 06:58 ET (10:58 GMT)